https://www.advanzpharma.com/news/2026/patent-settlement-secures-pathway-for-advanz-pharma-and-alvotech-to-market-eylea-biosimilar2026-01-30monthly1.0https://www.advanzpharma.com/news/2025/advanz-pharma-acquires-territory-rights-to-progynova-and-cyclo-progynova-in-selected-countries-in-emea-and-global-rights-to-ilomedin2025-12-18monthly1.0https://www.advanzpharma.com/news/2025/alvotech-and-advanz-pharma-receive-marketing-approval-across-the-european-economic-area-for-gobivaz-a-biosimilar-to-simponi-golimumab2025-11-20monthly1.0https://www.advanzpharma.com/news/2025/alvotech-and-advanz-pharma-receive-marketing-authorisations-for-gobivaz-a-biosimilar-to-simponi-golimumab-from-the-mhra2025-11-06monthly1.0https://www.advanzpharma.com/news/2025/advanz-pharma-acquires-global-rights-to-rare-disease-specialty-brand-zavesca2025-10-13monthly1.0https://www.advanzpharma.com/news/2025/european-marketing-application-for-avt23-a-proposed-biosimilar-to-xolair-omalizumab-accepted-by-the-european-medicines-agency2025-10-06monthly1.0https://www.advanzpharma.com/news/2025/european-medicines-agency-recommends-marketing-approval-of-gobivaz-alvotechs-proposed-biosimilar-to-simponi-golimumab-with-advanz-pharma-as-commercialization-partner2025-09-22monthly1.0https://www.advanzpharma.com/news/2025/advanz-pharma-and-alvotech-receive-european-approval-for-mynzepli-biosimilar-to-eylea2025-08-21monthly1.0https://www.advanzpharma.com/news/2025/alvotech-and-advanz-pharma-enter-into-european-supply-and-commercialization-agreement-for-biosimilar-candidate-to-cimzia-certolizumab-pegol2025-07-01monthly1.0https://www.advanzpharma.com/news/2025/positive-top-line-results-from-confirmatory-efficacy-study-for-proposed-biosimilar-to-xolair-omalizumab2025-06-25monthly1.0https://www.advanzpharma.com/news/2025/european-medicines-agency-recommends-market-approval-of-avt06-alvotechs-proposed-biosimilar-to-eylea-aflibercept2025-06-23monthly1.0https://www.advanzpharma.com/news/2025/advanz-pharma-acquires-testoviron-rights-from-bayer-in-europe-and-parts-of-latam-mea-and-apac2025-06-23monthly1.0https://www.advanzpharma.com/news/2025/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-three-additional-biosimilars-in-europe2025-05-28monthly1.0https://www.advanzpharma.com/news/2025/advanz-pharma-and-pharmathen-expand-strategic-partnership-with-exclusive-license-and-supply-agreement2025-05-15monthly1.0https://www.advanzpharma.com/news/2025/uk-medicines-and-healthcare-products-regulatory-agency-confirms-acceptance-of-marketing-authorization-application-for-proposed-biosimilar-to-xolair-omalizumab2025-03-26monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharma-acquires-the-rights-to-progynova-and-cyclo-progynova-in-selected-countries-in-apac-from-bayer2024-12-04monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharmas-response-to-the-reversal-of-the-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe2024-11-27monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharma-acquires-the-rights-to-nootropil-and-atarax-from-ucb-for-europe-and-selected-countries-in-latam-and-apac2024-11-05monthly1.0https://www.advanzpharma.com/news/2024/european-medicines-agency-confirms-acceptance-of-marketing-authorization-application-for-avt05-a-proposed-biosimilar-to-simponi-golimumab2024-11-04monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharma-releases-environmental-social-governance-esg-report-for-2023-20242024-10-04monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharma-secures-temporary-suspension-of-the-european-commission-decision-on-the-ocaliva-conditional-marketing-authorisation-in-europe2024-09-05monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharmas-response-to-european-commission-revocation-of-conditional-marketing-authorisation-for-ocaliva-in-rare-disease-primary-biliary-cholangitis-pbc2024-09-03monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharma-and-enzene-enter-an-exclusive-partnership-for-biosimilar-development-and-commercialisation2024-08-27monthly1.0https://www.advanzpharma.com/news/2024/european-medicines-agency-confirms-acceptance-of-marketing-application-for-avt06-a-proposed-biosimilar-to-eylea-aflibercept2024-08-15monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharma-response-to-chmp-recommendation-pertaining-to-eu-conditional-marketing-authorization-for-ocaliva-in-rare-disease-primary-biliary-cholangitis2024-07-01monthly1.0https://www.advanzpharma.com/news/2024/alvotech-and-advanz-pharma-sign-commercialization-agreement-for-proposed-biosimilar-to-eylea-ld-hd-in-europe2024-06-18monthly1.0https://www.advanzpharma.com/news/2021/advanz-pharma-enters-into-agreement-to-acquire-the-rights-to-eisais-zonegran-in-the-eu-middle-east-russia-and-australia2024-05-30monthly1.0https://www.advanzpharma.com/news/2021/nordic-capital-acquires-specialty-pharmaceutical-company-advanz-pharma-in-deal-worth-846-million2024-05-30monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharma-and-allecra-therapeutics-announce-approval-in-the-european-union-for-the-new-antibiotic-combination-exblifep-cefepime-enmetazobactam-for-the-treatment-of-severe-infections2024-03-27monthly1.0https://www.advanzpharma.com/news/2021/advanz-pharma-announces-launch-of-mytolac-in-germany-the-first-generic-lanreotide-for-the-treatment-of-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-gep-nets2024-03-22monthly1.0https://www.advanzpharma.com/news/2021/advanz-pharma-announces-launch-of-myrelez-in-norway-the-first-generic-lanreotide-for-the-treatment-of-acromegaly-and-gastroenteropancreatic-neuroendocrine-tumours-gep-nets2024-03-22monthly1.0https://www.advanzpharma.com/news/2021/advanz-pharma-makes-key-changes-to-senior-leadership-to-further-accelerate-next-phase-of-growth2024-03-22monthly1.0https://www.advanzpharma.com/news/2021/advanz-pharma-launches-its-first-environmental-social-and-governance-report2024-03-22monthly1.0https://www.advanzpharma.com/news/2024/advanz-pharma-receives-positive-chmp-opinion-for-exblifep-cefepime-enmetazobactam2024-01-26monthly1.0https://www.advanzpharma.com/news/2023/advanz-pharma-further-strengthens-its-global-portfolio-of-specialty-brands2024-01-19monthly1.0https://www.advanzpharma.com/news/2023/advanz-pharma-and-dimerix-enter-into-an-exclusive-license-agreement-to-commercialise-dmx-200-in-europe-canada-australia-and-new-zealand2024-01-19monthly1.0https://www.advanzpharma.com/news/2023/advanz-pharma-signs-an-exclusive-agreement-with-gp-pharm-for-a-peptide-specialty-injectable-generic-for-multiple-european-countries2024-01-19monthly1.0https://www.advanzpharma.com/news/2023/advanz-pharma-releases-environmental-social-governance-esg-report-for-2022-20232024-01-19monthly1.0https://www.advanzpharma.com/news/2023/alvotech-and-advanz-pharma-extend-strategic-partnership-to-commercialize-five-proposed-biosimilars-in-europe2024-01-19monthly1.0https://www.advanzpharma.com/news/2023/advanz-pharma-launches-palmeux-paliperidone-1-month-long-acting-injection-across-various-european-countries2024-01-19monthly1.0https://www.advanzpharma.com/news/2023/advanz-pharma-enters-into-an-exclusive-agreement-with-alvotech-to-commercialise-a-proposed-biosimilar-to-xolair-omalizumab2024-01-19monthly1.0https://www.advanzpharma.com/news/2023/advanz-pharma-to-receive-exclusive-rights-from-applied-therapeutics-to-commercialise-at-007-govorestat-in-europe2024-01-19monthly1.0https://www.advanzpharma.com/news/2022/advanz-pharma-further-strengthens-its-specialty-and-hospital-business-by-acquiring-an-anti-infective-portfolio-from-sanofi2024-01-19monthly1.0https://www.advanzpharma.com/news/2022/advanz-pharma-to-receive-exclusive-rights-from-polypid-to-commercialize-d-plex100-in-europe2024-01-19monthly1.0https://www.advanzpharma.com/news/2022/advanz-pharma-completes-acquisition-of-intercepts-business-in-europe-canada-and-all-other-markets-outside-of-the-u-s2024-01-19monthly1.0https://www.advanzpharma.com/news/2022/advanz-pharma-to-acquire-intercepts-business-in-europe-canada-and-all-other-markets-outside-of-the-u-s2024-01-19monthly1.0https://www.advanzpharma.com/news/2022/steffen-wagner-assumes-his-position-as-new-chief-executive-officer-at-advanz-pharma2024-01-19monthly1.0https://www.advanzpharma.com/news/2022/cidron-aida-finco-s-%C3%A0-r-l-successful-pricing-of-175-0-million-5-senior-secured-notes-due-20282024-01-19monthly1.0https://www.advanzpharma.com/news/2022/cidron-aida-finco-s-%C3%A0-r-l-proposed-offering-of-150-million-5-senior-secured-notes-due-20282024-01-19monthly1.0https://www.advanzpharma.com/news/2022/allecra-therapeutics-and-advanz-pharma-sign-exclusive-license-and-supply-agreement-for-allecras-antibiotic-cefepime-enmetazobactam-in-europe2024-01-19monthly1.0https://www.advanzpharma.com/news/2023/advanz-pharma-acquires-global-rights-to-androcur-from-bayer2024-01-19monthly1.0